Bristol-Myers signs deal with CytomX | Chemical & Engineering News
Volume 95 Issue 13 | p. 13 | Concentrates
Issue Date: March 27, 2017

Bristol-Myers signs deal with CytomX

Department: Business
Keywords: oncology, drug discovery, antibody, biopharmaceuticals, Bristol-Myers Squibb

Bristol-Myers Squibb and CytomX Therapeutics are expanding a drug discovery collaboration that dates back to 2014. To four ongoing projects the partners will add up to six cancer and two other drug targets using CytomX’s Probody technology. Bristol-Myers will pay $200 million up front, along with research funding and as much as $448 million in potential milestones for each new target. Probody therapeutics are designed to be activated by proteases in the tumor microenvironment.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment